Publications / Presentations

Additive effects of ALXN2420, a GH receptor antagonist, and octreotide on IGF1 suppression in vivo
European Journal of Endocrinology, 192(3):299-307 (2025)

Discovery of Truncated Cyclic Peptides Targeting an Induced-Fit Pocket on PCSK9
ChemMedChem, e202400208（2024）

The discovery and structural basis of two distinct state-dependent inhibitors of BamA
Nature Communications volume 15, Article number: 8718 (2024)

Peptide Binder to Glypican-3 as a Theranostic Agent for Hepatocellular Carcinoma
Journal of Nuclear Medicine February 2024, jnumed.123.266766

Exploration of macrocyclic peptide binders to the extracellular CRD domain of human receptor tyrosine kinase-like orphan receptor 1 (ROR1)
Bioorganic & Medicinal Chemistry Letters, 129589（2023）

A liquid-phase continuous-flow peptide synthesizer for preparing C-terminal free peptides
Reaction Chemistry & Engineering, 8, 863-870(2023)

Biochemical and Structural Characterization of a Peptidic Inhibitor of the YAP:TEAD Interaction That Binds to the α-Helix Pocket on TEAD
ACS Chemical Biology, 18(3):643-651（2023）

Peptide-to-Small Molecule: A Pharmacophore-Guided Small Molecule Lead Generation Strategy from High-Affinity Macrocyclic Peptides
Journal of Medicinal Chemistry, 65(15):10655-10673（2022）

Identification of a PCSK9-LDLR disruptor peptide with in vivo function.
Cell Chemical Biology, 29(2):249-258.e5（2022）

Discovery, X-ray structure and CPP-conjugation enabled uptake of p53/MDM2 macrocyclic peptide inhibitors
RSC Chemical Biology, 2(6):1661-1668（2021）

Extended Solution-phase Peptide Synthesis Strategy Using Isostearyl-Mixed Anhydride Coupling and a New C-Terminal Silyl Ester-Protecting Group for N-Methylated Cyclic Peptide Production
Organic Process Research & Development, 25 (9), 2029-2038 (2021)

Inhibition of Escherichia coli Lipoprotein Diacylglyceryl Transferase Is Insensitive to Resistance Caused by Deletion of Braun's Lipoprotein.
Journal of Bacteriology, 203(13):e0014921（2021）

Macrocyclic Peptides as a Novel Class of NNMT Inhibitors: A SAR Study Aimed at Inhibitory Activity in the Cell
ACS Medicinal Chemistry Letters, 12(7):1093-1101（2021）

Design of Thioether Cyclic Peptide Scaffolds with Passive Permeability and Oral Exposure.
Journal of Medicinal Chemistry, 64(5):2622-2633（2021）

Isostearyl Mixed Anhydrides for the Preparation of N-Methylated Peptides Using C-Terminally Unprotected N-Methylamino Acids
Organic Letters, 22(20):8039-8043（2020）

Constrained peptides in drug discovery and development
Yuki Gosei Kagaku Kyokaishi, 75(11):1171-1178（2017）

New trends in drug discovery and development by constrained peptides（Japanese Only）
Nippon Yakurigaku Zasshi, 148(6): 322-328（2016）

Charging of tRNAs using ribozymes and selection of cyclic peptides containing thioethers
Methods in Molecular Biology, 805:335-48（2012）

ASCO Genitourinary Cancers Symposium 2025 (February 2025, San Francisco)
First-in-Human Phase0 Safety, Imaging, Pharmacokinetics, and Dosimetry study of 64Cu-PD-32766, a Carbonic Anhydrase IX(CAIX)-Targeting Peptide, in Patients with Clear Cell Renal Cell Carcinoma (ccRCC) (presentation may be made available upon request)

The 10th Annual Meeting of the Japan Society of Urologic Oncology (October 2024, Fukuoka)
PD-32766, a CA-9-binding peptide, as potential radiotheranostic agent for renal cell carcinoma (presentation may be made available upon request)

American Association for Cancer Research (AACR) Annual Meeting 2024 (April 2024, San Diego)
A novel Carbonic Anhydrase IX targeting radiopeptide, 64Cu-PD-32766 and 177Lu-PD-32766, exhibit promising theranostic potential in ccRCC tumors. (presentation may be made available upon request)

Neuroscience 2023 (August 2023, Sendai)
Generation of Novel, Orally Active Selective Macrocyclic Peptide Inhibitors of Myostatin for Neuromuscular Diseases (presentation may be made available upon request)

World Muscle Society(WMS)2023 (October 2023, Charleston)
Generation of Novel, Orally Active Selective Macrocyclic Peptide Inhibitors of Myostatin for Neuromuscular Diseases (presentation may be made available upon request)

The 70th Annual Meeting of the Japanese Society for Virology (September 2023, Sendai)
Preclinical and Clinical Characterization of PA-001, a Macrocyclic Peptide That Targets the S2 Subunit of SARS-CoV-2 Spike Protein (presentation may be made available upon request)

2023 Endocrine Society Meeting (ENDO) (June 2023, Chicago)
Repeated Treatment with AZP-3813, a Bicyclic, 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor, Induces Enhanced Suppression of IGF1 in Beagle Dogs (presentation may be made available upon request)

2023 European Congress of Endocrinology (ECE) (May 2023, Istanbul)
AZP-3813, a Bicyclic, 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor, Effectively Suppresses IGF1 in Beagle Dogs (presentation may be made available upon request)

EASL Liver Cancer Summit 2023 (April 2023, Estoril)
GPC3 targeted radiopharmaceutical therapy for HCC: Preclinical characterization of a novel peptide binder (presentation may be made available upon request)

Flow Chemistry European Summit 2023 (March 2023, Rotterdam)
A Liquid-Phase Continuous-Flow Peptide Synthesizer for Preparing C-terminal Free Peptides (presentation may be made available upon request)

AAPS 2022 PHARMSCI 360 (October 2022, Boston)
How to Improve in Solubility of Water-Insoluble Cyclic Peptide with HA nanogel : Over 100,000-Fold Solubilization (presentation may be made available upon request)

The 62nd Annual Scientific Meeting of the Japanese Society of Nuclear Medicine(JSNM) / The 42nd Annual Meeting of the Japanese Society of Nuclear Medicine Technology(JSNMT) (September 2022, Kyoto)
The Next Generation Radiopharmaceuticals in PDRadiopharma.Inc (presentation may be made available upon request)

2022 Endocrine Society Meeting (ENDO) (June 2022, Atlanta)
Sustained Suppression of IGF1 with AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor and a Potential New Treatment for Acromegaly (presentation may be made available upon request)

2022 European Congress of Endocrinology (ECE) (May 2022, Milan)
AZP-3813, a Bicyclic 16-Amino Acid Peptide Antagonist of the Human Growth Hormone Receptor as a Potential New Treatment for Acromegaly (presentation may be made available upon request)